ClinicalTrials.gg
CompletedNCT05418101Updated Apr 15, 2026

A Study to Evaluate the Safety, PK and PD of VIS171 in Participants (Healthy and With Autoimmune Disease)

A Phase 1 interventional study of VIS171 and Placebo in Autoimmune Diseases, sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.. Completed at 10 sites in 5 countries. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-15.

Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc. (part of Otsuka Holdings Co., Ltd.) · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Mar 2024, 2 years 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 21 studies in Autoimmune Diseases with a site in Bulgaria — 4 open to participants now, 10 under way, 6 of them phase 3. Autoimmune Diseases · Bulgaria.

Enrollment
17th of 21
61 · median 171
Started
2022
with 2 others
Phase 1
4 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
2 of 21
Otsuka Pharmaceutical Development & Commercialization, Inc.

Among the 21 studies in Autoimmune Diseases with a site in Bulgaria, this one is the 17th largest by enrollment, is one of 3 that started in 2022, is one of 4 in phase 1, and was the 11th registered.

Autoimmune Diseases

803 studies on the registry are indexed under Autoimmune Diseases; 272 are open to participants now.

Browse Autoimmune Diseases studies →

Open to participants now

4 of the 21 studies in Autoimmune Diseases with a site in Bulgaria are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Bulgaria have not opened yet or have stopped. Only those recruiting at a site in Bulgaria →

Who these studies take

Of the 195 Autoimmune Diseases studies recruiting now, 90 (46%) set no upper age limit and 79 (41%) stop at 75 or younger; 55 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Autoimmune Diseases with a site in Bulgaria, or all of them as a file.
02

Study summary

This is a phase 1 study to evaluate the safety, tolerability, pharmacodynamics, and pharmacokinetics of VIS171 in healthy participants and in participants with autoimmune disease(s).

Read the detailed description

This is a multicenter, 2-part combined Single ascending dose (SAD) and Multiple ascending dose (MAD) First-in-Human (FIH) study to investigate the safety, tolerability, pharmacodynamics (PD), and pharmacokinetics (PK) of subcutaneous (SC) VIS171 in healthy participants (Part A - SAD) and in participants with autoimmune inflammatory disease(s) (Part B - MAD).

Part A: Part A is a randomized, double-blind, placebo controlled SAD assessment of SC VIS171 in healthy participants. Up to 5 cohorts are planned, each comprising 8 participants (6 VIS171 and 2 placebo).

Part B: Part B is an open-label, MAD basket assessment of SC VIS171 in participants with autoimmune inflammatory disease(s). Two to 3 cohorts are planned, each comprising 12 participants.

03

Conditions studied

  • Autoimmune Diseases

Browse trials for

Keywords

  • Safety
  • Tolerability
  • Pharmacodynamics
  • Pharmacokinetics
  • Healthy participants
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

Inclusion criteria for both Part A and Part B:

  • Male or female participant between 18 and 55 years of age, inclusive, at the screening visit (Part A and Part B [participants with selected diseases]) or between 18 and 75 years of age, inclusive, at the screening visit (Part B [participants with specific autoimmune disease]).
  • between 17 and 35 kg/m\^2.
  • Female participants will be nonpregnant, nonlactating, and either for at least 2 years or surgically sterile for at least 3 months.
  • Male participants with female partners of must agree to use double barrier or abstain from sex during the study and until 90 days following the last dose of study intervention.

Additional inclusion criterion for Part A:

- Healthy, as determined by prestudy medical evaluation (medical history, physical examination, vital signs, 12-lead , and clinical laboratory evaluations).

Additional inclusion criteria for Part B (participants with specific autoimmune disease[s]):

  • Diagnosis of a specified autoimmune disease based on standard criteria for the condition.
  • Other criteria may apply depending on the autoimmune condition.

Exclusion Criteria:

Exclusion criteria for both Part A and Part B:

Prior and Concomitant Therapy

  • Receipt of high dose therapy within 4 weeks prior to screening.
  • Receipt of belimumab within 6 months prior to screening.
  • History of treatment with rituximab or ocrelizumab (or other B cell-depleting agent) within 12 months prior to screening.
  • History of cytotoxic medications within the preceding 12 months.
  • Receipt of blood products within 6 months prior to screening.

Prior/Concurrent Clinical Study Experience:

  • Receipt of any product within 4 weeks or 5 half-lives of the respective product prior to signing of the ICF, whichever is greater.
  • Currently participating in another clinical study of any investigational drug, device, or intervention.

Diagnostic Assessments

  • Participants with uncontrolled hypertension (systolic blood pressure > 140 mmHg, diastolic blood pressure > 90 mmHg in any position) or symptomatic hypotension.
  • Any chronic infectious disease.
  • Participant with a positive urine drug or alcohol breath screen test result at screening.

Other Exclusions:

  • Any participant who has a history of alcohol or drug/chemical abuse.
  • Participant who has donated > 500 mL of blood within 60 days prior to the start of screening or any plasma within 7 days prior to baseline (Day -1).
  • History of opportunistic infection requiring hospitalization or intravenous (IV) antimicrobial treatment within 1 year prior to randomization.
  • History of major surgery within 12 weeks of screening or will require major surgery during the study.
  • electrocardiographic abnormalities, at screening.
  • A corrected for heart rate using Fridericia's correction (QTcF) > 450 msec for male participants or > 470 msec for female participants at screening.
  • Participant has received an organ transplant.
  • History of any significant cardiovascular disease or thrombotic episode.
  • History of cancer, apart from: squamous or basal cell carcinoma of the skin that has been successfully treated; cervical cancer in situ that has been successfully treated.
  • Coronavirus Disease 2019 (COVID-19): current symptoms of infection; diagnosis of COVID-19 in the 21 days prior to Screening; ongoing diagnosis of "Long-COVID" symptoms.
  • Received a vaccination, other than COVID-19 vaccination, during the 30 days prior to administration of the first dose of study intervention. A COVID-19 vaccination cannot be received within 7 days prior to the first dose of study intervention and until 14 days after the last dose.

Additional exclusion criteria for Part A:

Medical Conditions

  • Participant has a history or current evidence of a serious and/or unstable cardiovascular, respiratory, gastrointestinal, hematologic, autoimmune, blood dyscrasias or other medical disorder, including psychiatric disorders, cirrhosis, or .
  • Participant has a history or presence of proteinuria, chronic kidney disease, disease requiring therapy (including systemic steroids), or is considered to be immunosuppressed for any other reason.
  • History of a previous severe allergic reaction with generalized urticaria; angioedema or anaphylaxis.
  • Known immunodeficiency disorder.
  • History of chronic infection or any infection requiring hospitalization or treatment with antivirals, antibiotics, or antifungal therapy within 30 days prior to administration of the study intervention.
  • (ALT) or aspartate transaminase (AST) > 1.5 × the (ULN).
  • Total > 1.5 × ULN (isolated bilirubin > 1.5 × ULN is acceptable if total bilirubin is fractionated and direct bilirubin \< 35%).
  • Known hepatic or biliary abnormalities.

Additional exclusion criterion for Part A and Part B (participants with participants with specific autoimmune disease may apply depending upon the autoimmune condition).

Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Part A Cohort 1: Dose level 1

    Participants will be randomized to SAD dose of VIS171 (or placebo).

    Drug: VIS171 · Drug: Placebo

  • Experimental
    Part A Cohort 2: Dose level 2

    Participants will be randomized to SAD dose of VIS171 (or placebo).

    Drug: VIS171 · Drug: Placebo

  • Experimental
    Part A Cohort 3: Dose level 3

    Participants will be randomized to SAD dose of VIS171 (or placebo).

    Drug: VIS171 · Drug: Placebo

  • Experimental
    Part A Cohort 4: Dose level 4

    Participants will be randomized to SAD dose of VIS171 (or placebo).

    Drug: VIS171 · Drug: Placebo

  • Experimental
    Part A Cohort 5: Dose level 5

    Participants will be randomized to SAD dose of VIS171 (or placebo).

    Drug: VIS171 · Drug: Placebo

  • Experimental
    Part B Cohort 1: Dose level to be determined from SAD Cohort(s) data

    Participants will be randomized to MAD dose of VIS171.

    Drug: VIS171

  • Experimental
    Part B Cohort 2: Dose level to be determined from SAD Cohort(s) data

    Participants will be randomized to MAD dose of VIS171.

    Drug: VIS171

  • Experimental
    Part B Cohort 3: Dose level and regimen to be determined from prior MAD and SAD Cohort(s)

    Participants will be randomized to MAD dose of VIS171.

    Drug: VIS171

Interventions

  • DrugVIS171

    Participants will receive VIS171 via SC route of administration.

  • DrugPlacebo

    Participants will receive Placebo via SC route of administration

06

What researchers measure

Primary outcomes

  1. Part A and Part B: Numbers of participants with treatment-emergent adverse events (TEAEs)

    Time frame: Part A: From screening up to Day 29; Part B: From screening up to Day 71

Secondary outcomes

  1. Part A and Part B: Mean change from baseline in absolute number (cells/μL) for Treg, helper T cells, cytotoxic T cells and natural killer cells

    Time frame: Part A: From baseline up to Day 29; Part B: From baseline up to Day 71

  2. Part A and Part B: Mean change from baseline in percentage for Treg, helper T cells, cytotoxic T cells and natural killer cells

    Time frame: Part A: From baseline up to Day 29; Part B: From baseline up to Day 71

  3. Part A and Part B: Maximum (peak) plasma VIS171 concentration (Cmax) over time

    Time frame: Part A: From baseline up to Day 29; Part B: From baseline up to Day 71

  4. Part A and Part B: Time of maximum (peak) plasma VIS171 concentration (tmax)

    Time frame: Part A: From baseline up to Day 29; Part B: From baseline up to Day 71

  5. Part A: Area under the concentration-time curve from time zero to the last observable concentration (AUClast) of VIS171

    Time frame: Part A: From baseline up to Day 29

  6. Part A: Area under the concentration-time curve from time zero to infinity (AUC∞) for VIS171 concentration

    Time frame: Part A: From baseline up to Day 29

  7. Part B: Area under the concentration-time curve over the dosing interval at steady-state (AUCtau)

    Time frame: Part B: From baseline up to Day 71

  8. Part A and Part B: Number of participants with Anti-drug antibodies (ADA) positive for VIS171

    Time frame: Part A: Day 1, 15, and 29; Part B: Day 1, 15, 29, 43, and 71

07

Study locations

10 sites
  • UMHAT
    Plovdiv, 4002, Bulgaria
  • Ambulatory for Specialized Medical Help - skin and venereal diseases
    Sofia, 1407, Bulgaria
  • Comac Medical Ltd
    Sofia, 1612, Bulgaria
  • MBAL Sveta Sofia
    Sofia, 1618, Bulgaria
  • Diagnostic and Consultative Center Convex EOOD
    Sofia, 1680, Bulgaria
  • Universitaetsklinikum Bonn AöR
    Bonn, 53127, Germany
  • Universitätsmedizin der Johannes-Gutenberg-Universität Mainz
    Rheinland-Pfalz, 55131, Germany
  • Clinical republican Hospital
    Chisinau, MD 2025, Moldova
  • Radboud University Medical Center
    Gelderland, 6525, Netherlands
  • New Zealand Clinical Research
    Christchurch, 8011, New Zealand
08

References and documents

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2022 to primary completion in Mar 2024, 22 months.

Of 69 industry-sponsored phase 1 interventional studies under Autoimmune Diseases, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 32. This study's 22 months is above that.

Counting every sponsor, half of 95 studies reached it within 23 months; a quarter within 9 and three quarters within 36.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 3, 2022
First posted
Jun 14, 2022
StartActual
Apr 28, 2022
Primary completionActual
Mar 13, 2024
CompletionActual
Mar 13, 2024
Last update
Apr 15, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 15, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05418101
Responsible party
Sponsor
First posted
Jun 14, 2022
Start date
Apr 28, 2022
Primary completion
Mar 13, 2024
Completion
Mar 13, 2024
Last update
Apr 15, 2026

Study contacts

Asher Schachter, MD
principal investigator · Visterra, Inc.

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion